We randomly assigned 536 women who had undergone either a modified radical mastectomy or a total mastectomy with low axillary-node dissection for potentially curable breast carcinoma to receive adjuvant chemotherapy or no-treatment observation. The patients were considered at high risk for recurrence because they had either an estrogen-receptor-negative tumor of any size or an estrogen-receptor-positive tumor at least 3 cm in diameter with no histopathological evidence of axillary-node involvement. The chemotherapy consisted of six four-week cycles of cyclophosphamide (100 mg per square meter of body-surface area orally on days 1 through 14), methotrexate (40 mg per square meter intravenously on days 1 and 8), fluorouracil (600 mg per square meter intravenously on days 1 and 8), and prednisone (40 mg per square meter orally on days 1 through 14). Treatments were balanced with respect to patients' characteristics. The analysis included 406 eligible patients who were entered in the study before October 1, 1987. The overall disease-free survival among patients treated with the four-drug regimen was 84 percent, as compared with 69 percent for the control group, at a median follow-up of three years (P = 0.0001). A treatment benefit was also observed in premenopausal and postmenopausal patients as well as in patients with estrogen-receptor-positive or with estrogen-receptor-negative tumors. Severe or life-threatening hematologic toxicity was encountered in 33 percent of the treated patients, with one death. Our results indicate that adjuvant chemotherapy with six cycles of cyclophosphamide, methotrexate, fluorouracil, and prednisone is effective in improving three-year disease-free survival among high-risk patients with axillary-node-negative, operable breast cancer. An analysis of the effect of treatment on survival awaits a longer follow-up.
Source Information
Cleveland Metropolitan General Hospital, Case Western Reserve University, OH 44109.
This article has been cited by other articles:
Goldstein, L. J., O'Neill, A., Sparano, J. A., Perez, E. A., Shulman, L. N., Martino, S., Davidson, N. E.
(2008). Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197. JCO
26: 4092-4099
[Abstract][Full Text]
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., Levine, M. N., the National Cancer Institute of Canada Clinical T,
(2006). HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. NEJM
354: 2103-2111
[Abstract][Full Text]
Hutchins, L. F., Green, S. J., Ravdin, P. M., Lew, D., Martino, S., Abeloff, M., Lyss, A. P., Allred, C., Rivkin, S. E., Osborne, C. K.
(2005). Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102. JCO
23: 8313-8321
[Abstract][Full Text]
Albain, K. S.
(2004). Adjuvant Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: A Tale of Three Trials. JNCI J Natl Cancer Inst
96: 1801-1804
[Full Text]
Bull, S. B., Ozcelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A.J., Pritchard, K. I., Tzontcheva, A. T., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., Tweeddale, M. E., Fine, S., McCready, D. R., Andrulis, I. L.
(2004). The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. JCO
22: 86-96
[Abstract][Full Text]
International Breast Cancer Study Group,
(2003). Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. JNCI J Natl Cancer Inst
95: 1833-1846
[Abstract][Full Text]
Mariotto, A., Feuer, E. J., Harlan, L. C., Wun, L.-M., Johnson, K. A., Abrams, J.
(2002). Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999. JNCI J Natl Cancer Inst
94: 1626-1634
[Abstract][Full Text]
Hansen, N. M., Grube, B. J., Giuliano, A. E.
(2002). The Time Has Come to Change the Algorithm for the Surgical Management of Early Breast Cancer. Arch Surg
137: 1131-1135
[Abstract][Full Text]
Paradiso, A., Schittulli, F., Cellamare, G., Mangia, A., Marzullo, F., Lorusso, V., De Lena, M.
(2001). Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer. JCO
19: 3929-3937
[Abstract][Full Text]
Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., Dimitrov, N. V., Atkins, J. N., Abramson, N., Merajver, S., Romond, E. H., Kardinal, C. G., Shibata, H. R., Margolese, R. G., Farrar, W. B.
(2001). Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23. JCO
19: 931-942
[Abstract][Full Text]
Gerber, B., Krause, A., Muller, H., Richter, D., Reimer, T., Makovitzky, J., Herrnring, C., Jeschke, U., Kundt, G., Friese, K.
(2001). Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors. JCO
19: 960-971
[Abstract][Full Text]
Fisher, B., Dignam, J., Tan-Chiu, E., Anderson, S., Fisher, E. R., Wittliff, J. L., Wolmark, N.
(2001). Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes. JNCI J Natl Cancer Inst
93: 112-120
[Abstract][Full Text]
Reed, D. N. Jr, Johnson, J., Richard, P., McCormick, S., Shannon, N., Mikhail, R. A., Osuch, J., Cerrito, P. B., McMasters, K. M.
(2000). DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer. Arch Surg
135: 1422-1426
[Abstract][Full Text]
Amadori, D., Nanni, O., Marangolo, M., Pacini, P., Ravaioli, A., Rossi, A., Gambi, A., Catalano, G., Perroni, D., Scarpi, E., Giunchi, D. C., Tienghi, A., Becciolini, A., Volpi, A.
(2000). Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study. JCO
18: 3125-3134
[Abstract][Full Text]
Thames, H. D., Buchholz, T. A., Smith, C. D.
(1999). Frequency of First Metastatic Events in Breast Cancer: Implications for Sequencing of Systemic and Local-Regional Treatment. JCO
17: 2649-2649
[Abstract][Full Text]
Wils, J.A., Bliss, J.M., Marty, M., Coombes, G., Fontaine, C., Morvan, F., Olmos, T., Perez-Lopez, F.R., Vassilopoulos, P., Woods, E., Coombes, R.C.
(1999). Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group. JCO
17: 1988-1988
[Abstract][Full Text]
Hebert-Croteau, N., Brisson, J., Latreille, J., Gariepy, G., Blanchette, C., Deschenes, L.
(1999). Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer. JCO
17: 1458-1458
[Abstract][Full Text]
Daugherty, C. K.
(1999). Impact of Therapeutic Research on Informed Consent and the Ethics of Clinical Trials: A Medical Oncology Perspective. JCO
17: 1601-1601
[Abstract][Full Text]
Ollila, D. W., Brennan, M. B., Giuliano, A. E.
(1998). Therapeutic Effect of Sentinel Lymphadenectomy in T1 Breast Cancer. Arch Surg
133: 647-651
[Abstract][Full Text]
(1989). ADJUVANT SYSTEMIC THERAPY FOR NODE-NEGATIVE BREAST CANCER. JWatch General
1989: 1-1
[Full Text]
Previous
